PMID- 8391243
OWN - NLM
STAT- MEDLINE
DCOM- 19930728
LR  - 20071114
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 13
IP  - 3
DP  - 1993 May-Jun
TI  - Heterotransplantation of human multiple myeloma cell lines in severe combined 
      immunodeficiency (SCID) mice.
PG  - 593-7
AB  - Human multiple myeloma (MM) xenografts have been difficult to establish in 
      athymic mice. We examined the feasibility of establishing human MM xenograft 
      growth in SCID mice following subcutaneous (sc) injection of 1-2 x 10(7) cells 
      from the human plasma cell dyscrasia (PCD) cell lines RPMI 8226 and ARH-77. SC 
      tumors emerged in 67% (6/9) of RPMI 8226- and 6 of 6 ARH-77-injected mice after a 
      latency period of 9-54 days, and reached 19-35 mm in diameter before the mice 
      were sacrificed. RPMI 8226 and ARH-77 primary tumor DNA hybridized positively 
      with the human genome probe Alul-(Blur8), confirming successful engraftment of 
      the human MM cell lines. The RPMI 8226 xenografts comprised predominantly of 
      plasmacytoid cells that expressed the relevant cytoplasmic immunoglobulin (cIg) 
      light chain isotype. Xenografted RPMI 8226 cells also expressed CD10 (CALLA; 44% 
      reactive cells), CD38 (OKTIO; 69%), CD5 (49%), and reacted with the MM monoclonal 
      antibody MM4 (39%). Human MM growth appeared to be localized subcutaneously for 
      both RPMI 8226 and ARH-77 xenografts. There were no detectable metastatic foci in 
      kidney, brain, heart, or bone marrow. Whereas diffuse plasma cell infiltrates 
      were observed in spleen, GI tract, and lung biopsies of tumor-bearing mice, these 
      infiltrates were of host origin according to immunophenotyping and DNA analyses. 
      Neither the originating RPMI 8226 line nor its SCID mouse xenograft expressed 
      Epstein Barr virus (EBV) genome sequences. These observations indicate that both 
      EBV- (RPMI 8226) and EBV+ (ARH-77) cell lines can be successfully propagated in 
      SCID mice.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Tong, A W
AU  - Tong AW
AD  - Cancer Immunology Research Laboratory, Charles A. Sammons Cancer Center, Baylor 
      University Medical Center, Dallas, Texas 75246.
FAU - Huang, Y W
AU  - Huang YW
FAU - Zhang, B Q
AU  - Zhang BQ
FAU - Netto, G
AU  - Netto G
FAU - Vitetta, E S
AU  - Vitetta ES
FAU - Stone, M J
AU  - Stone MJ
LA  - eng
GR  - CA-28149/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Myeloma Proteins)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal
MH  - Antigens, Neoplasm/*analysis
MH  - Cell Line, Transformed
MH  - Feasibility Studies
MH  - Genome, Human
MH  - Genome, Viral
MH  - Herpesvirus 4, Human/genetics
MH  - Humans
MH  - Mice
MH  - Mice, SCID
MH  - *Multiple Myeloma/genetics/immunology/pathology
MH  - Myeloma Proteins/*analysis
MH  - *Neoplasm Transplantation
MH  - *Transplantation, Heterologous
MH  - Tumor Cells, Cultured/immunology/pathology
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1993 May-Jun;13(3):593-7.